Skip to main content

Table 6 Major adverse events in study subjects with SLE

From: Association between low-dose pulsed intravenous cyclophosphamide therapy and amenorrhea in patients with systemic lupus erythematosus: A case-control study

Adverse events* IVCY group Steroid group
  n = 29 n = 33
Amenorrhea 17 (59%) 9 (27%)
Elevation of liver enzymes 2 (7%) 0 (0%)
Hematological disorder 1 (3%) 0 (0%)
Herpes Zoster infection 1 (3%) 2 (6%)
Cytomegalovirus infection 0 (0%) 1 (3%)
Tinea corporis 0 (0%) 1 (3%)
Myocarditis 1 (3%) 0 (0%)
  1. *Adverse events that are usually not regarded as IVCY-related are excluded from this table.
  2. IVCY intravenous cyclophosphamide, SLE systemic lupus erythematosus.